You are here
The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.
TGA business plan 2013-2014
Therapeutic Goods Administration
Funding, capital expenditure and anticipated revenue
Our finances are managed through the Therapeutic Goods Special Account (under Section 21 of the Financial Management and Accountability Act 1997).
The Portfolio Budget Statements includes expenses totalling $148.428 million for the TGA for 2013-14. The appropriations include funding of the new budget measure on High Risk Implantable devices of $3.577m and interest equivalency. ANZTPA departmental and administered funding is held by Health Central Office and not by the TGA.
2013-14 Portfolio budget statements
|TGA Special Account||$131,310,000||$148,428,000|
|Budgeted increase in expenditure (including capital) comprises:|
|Estimated Actual 2012-13||$131,310,000|
|Employee expenses increase (2.5% per Health Enterprise Agreement)||$2,175,000|
|Business improvement and general increase (e.g. rent)||$2,976,000|
|New Policy Proposal (NPP) - High Risk Implantable Device Registers*||$3,577,000|
|Business Systems Upgrade (reallocation of funding from TGA reserves)†||$8,390,000|
|Budgeted expenses 2013-14 (including capital)||$148,428,000|
* The funding for registers is mainly for work done by other parts of Health, and for contracting groups developing the registers. The TGA expects to retain only a small amount of the funding for its work program
† Funds allocated from cash reserves held in the TGA special account. This allocation was approved in the 2013-14 Budget for the development of new business systems to support the future requirements of the TGA and its industry stakeholders. The new systems will improve efficiency and transparency and be consistent with transition to ANZTPA.
Out year 1
Out year 2
Out year 3
|Approved internally funded projects‡||$5,052,500||$6,507,900||$5,355,900||$6,939,000|
‡Note: Excludes the Business Systems Upgrade project as a business case has not yet been endorsed.